Rivernorth Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Rivernorth Capital Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.23M	Hold	198,730	–	–	0.16%	183
2025 Q4	$3.33M	Sell	198,730 -108,907	-35%	-$1.83M	0.16%	194
2025 Q3	$4.77M	Buy	307,637 +77,793	+34%	+$1.07M	0.27%	98
2025 Q2	$2.94M	Buy	229,844 +67,161	+41%	+$828K	0.16%	168
2025 Q1	$2.06M	Buy	162,683 +122,869	+309%	+$1.66M	0.11%	168
2024 Q4	$522K	Buy	+39,814	New	+$574K	0.03%	206

Other funds holding HQL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Rivernorth Capital Management's HQL Position: Q1 2026 in Review

Rivernorth Capital Management held its abrdn Life Sciences Investors (HQL) position steady in Q1 2026 at 198,730 shares worth $3.23M. The position accounts for 0.16% of the portfolio, ranked #183.

Rivernorth Capital Management first reported a position in HQL in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.77M in Q3 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

Rivernorth Capital Management held 198,730 shares of abrdn Life Sciences Investors worth $3.23M as of Q1 2026.
Rivernorth Capital Management left its abrdn Life Sciences Investors share count unchanged in Q1 2026.
abrdn Life Sciences Investors made up 0.16% of Rivernorth Capital Management's portfolio in Q1 2026, its #183 holding.
Rivernorth Capital Management first reported a position in abrdn Life Sciences Investors in Q4 2024 and has held it in 6 quarters since.
Rivernorth Capital Management's abrdn Life Sciences Investors position peaked at $4.77M in Q3 2025.
86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Rivernorth Capital Management's 13F filing for Q1 2026, filed 15 May 2026.